These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31309775)

  • 1. Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens.
    Schioppo T; Scalone L; Cozzolino P; Mantovani L; Cesana G; De Lucia O; Murgo A; Ingegnoli F
    Reumatismo; 2019 Jul; 71(2):62-67. PubMed ID: 31309775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial.
    Schioppo T; Orenti A; Boracchi P; De Lucia O; Murgo A; Ingegnoli F
    Rheumatology (Oxford); 2018 Aug; 57(8):1408-1416. PubMed ID: 29733400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens.
    Barsotti S; Lorenzoni V; Di Battista M; d'Ascanio A; Silvia B; Puccetti L; Turchetti G; Della Rossa A; Mosca M
    Scand J Rheumatol; 2021 Jul; 50(4):307-313. PubMed ID: 33622195
    [No Abstract]   [Full Text] [Related]  

  • 5. Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.
    Bixio R; Adami G; Bertoldo E; Giollo A; Morciano A; Bertelle D; Orsolini G; Idolazzi L; Rossini M; Viapiana O
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221137125. PubMed ID: 36439640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of iloprost in systemic sclerosis in a real-life experience.
    Bellando-Randone S; Bruni C; Lepri G; Fiori G; Bartoli F; Conforti ML; Moggi-Pignone A; Guiducci S; Giuggioli D; Colaci M; Spinella A; Ferri C; Matucci-Cerinic M
    Clin Rheumatol; 2018 May; 37(5):1249-1255. PubMed ID: 29470737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and persistence of intravenous iloprost in systemic sclerosis.
    Martins P; Dourado E; Fonseca JE; Romão V; Resende C
    ARP Rheumatol; 2022; 1(2):122-128. PubMed ID: 35810370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
    Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
    Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis.
    Cutolo M; Ruaro B; Pizzorni C; Ravera F; Smith V; Zampogna G; Paolino S; Seriolo B; Cimmino M; Sulli A
    J Rheumatol; 2014 May; 41(5):881-6. PubMed ID: 24692525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
    Trombetta AC; Pizzorni C; Ruaro B; Paolino S; Sulli A; Smith V; Cutolo M
    J Rheumatol; 2016 Nov; 43(11):2033-2041. PubMed ID: 27744392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
    Cutolo M; Zampogna G; Vremis L; Smith V; Pizzorni C; Sulli A
    J Rheumatol; 2013 Jan; 40(1):40-5. PubMed ID: 23118114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study.
    Negrini S; Magnani O; Matucci-Cerinic M; Carignola R; Data V; Montabone E; Santaniello A; Adorni G; Murdaca G; Puppo F; Indiveri F; Della Rossa A; D'Ascanio A; Barsotti S; Giuggioli D; Ferri C; Lumetti F; Bosello SL; Canestrari G; Bellando Randone S; Bruni C; Guiducci S; Battaglia E; De Andres MI; Russo AA; Beretta L
    Clin Exp Med; 2019 Aug; 19(3):357-366. PubMed ID: 30989453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term effects of cyclic therapy with iloprost in systemic sclerosis].
    Scarsi M; Rossi M; Danieli E; Frigè A; Grottolo A; Zambruni A; Airò P
    Reumatismo; 2008; 60(2):114-9. PubMed ID: 18651055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of response to iloprost evaluated by laser speckle contrast analysis in systemic sclerosis.
    Di Battista M; Da Rio M; Logiacco A; Barsotti S; Della Rossa A; Mosca M
    Scand J Rheumatol; 2023 May; 52(3):302-305. PubMed ID: 35880719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.